CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 66 enrolled
Drug / intervention
S-citalopram +2 moredrug
Likely dose
S-citalopram 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00655057
NCT00655057Phase 3Completed
CompareCT.gov

SPECT Brain Imaging as a Bio-Marker of Major Depression

University of Pennsylvania·interventional·Posted Apr 9, 2008·Updated Apr 16, 2020

In Brief

A Phase 3 clinical trial evaluating S-citalopram, Cognitive behavioral therapy (CBT), and 1 other intervention for Depression. Completed, enrolled 66 participants across 1 site.

Detailed Summary

This study will examine changes in brain dopamine transporter activity before and after antidepressant therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 9, 2008
Enrollment StartOct 1, 2005
Primary CompletionAug 1, 2009
Study CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 18.2 years ago

Interventions

S-citalopramdrug

Participants will take 10 to 30 mg of s-citalopram daily for 12 weeks.

Cognitive behavioral therapy (CBT)behavioral

Participants will attend twice weekly CBT sessions for 2 weeks and then once weekly sessions for 10 weeks. Sessions will focus on modifying thoughts and behaviors that may contribute to depression.

TRODAT-1 single photon emission computed tomographic (SPECT) imagingprocedure

Participants' striatal dopamine transporter (DAT) levels will be measured using \[99mTc\]TRODAT-1 SPECT with magnetic resonance imaging (MRI) co-localization on two separate occasions. Participants with depression will undergo TRODAT-1 SPECT imaging immediately before and after 12 weeks of their assigned treatment. Healthy participants will undergo TRODAT-1 SPECT imaging at baseline and 12 weeks later.